Demir Tamer, Gödekmerdan Ahmet, Balbaba Mehmet, Türkçüoglu Peykan, Ilhan Fulya, Demir Nesrin
Firat University School of Medicine, Department of Ophthalmology, Elazig, Turkey.
Indian J Ophthalmol. 2006 Dec;54(4):241-5. doi: 10.4103/0301-4738.27948.
To identify the effect of infliximab, cyclosporine A and recombinant IL-10 in experimental autoimmune uveitis.
Sixty male rats were assigned to five groups of 12 each. All the groups (except the control group) were administered 30 microg retinal-S antigen intraperitoneally. On the 14th day, after confirmation of uveitis with histopathological study, daily cyclosporine A injection was given in cyclosporine A treatment group and physiological serum in the uveitis-induced placebo treatment and control groups. In the infliximab treatment group, infliximab was administered on the 14th, 15th, 17th, 19th and 21st days. In the recombinant IL-10 treatment group, three doses of recombinant IL-10 were given four hours and a half hours before and eight hours after retinal-S antigen administration. On the 21st day of the study, all rats were sacrificed and vitreous cytokine levels (IL-1, IL-6, IL-8 and TNF-alpha) were studied with ELISA.
In the treatment groups, cytokine levels (IL-1, IL-6 and TNF-alpha) were significantly lower than the uveitis-induced placebo treatment group. Compared with the control group, there was no significant difference with respect to TNF-alpha and IL-8 in the infliximab treatment group; IL-8 in the cyclosporine A treatment group; IL-6 and IL-8 in the recombinant IL-10 treatment group. The drugs used did not significantly differ in respect to their effects on vitreous IL-6, IL-8 and TNF-alpha levels.
Cyclosporine A, infliximab and recombinant IL-10 reduce the vitreous cytokines levels. Among these drugs, recombinant IL-10, which is still in its experimental phase, might be considered as a new therapeutic agent.
确定英夫利昔单抗、环孢素A和重组白细胞介素-10在实验性自身免疫性葡萄膜炎中的作用。
将60只雄性大鼠分为5组，每组12只。所有组（除对照组外）腹腔注射30微克视网膜S抗原。在第14天，经组织病理学研究证实葡萄膜炎后，环孢素A治疗组每日注射环孢素A，葡萄膜炎诱导的安慰剂治疗组和对照组注射生理血清。在英夫利昔单抗治疗组，于第14、15、17、19和21天给予英夫利昔单抗。在重组白细胞介素-10治疗组，在视网膜S抗原给药前4.5小时、给药后8小时给予三剂重组白细胞介素-10。在研究的第21天，处死所有大鼠，用酶联免疫吸附测定法研究玻璃体液中细胞因子水平（白细胞介素-1、白细胞介素-6、白细胞介素-8和肿瘤坏死因子-α）。
在治疗组中，细胞因子水平（白细胞介素-1、白细胞介素-6和肿瘤坏死因子-α）显著低于葡萄膜炎诱导的安慰剂治疗组。与对照组相比，英夫利昔单抗治疗组的肿瘤坏死因子-α和白细胞介素-8；环孢素A治疗组的白细胞介素-8；重组白细胞介素-10治疗组的白细胞介素-6和白细胞介素-8无显著差异。所用药物对玻璃体液中白细胞介素-6、白细胞介素-8和肿瘤坏死因子-α水平的影响无显著差异。
环孢素A、英夫利昔单抗和重组白细胞介素-10可降低玻璃体液中细胞因子水平。在这些药物中，仍处于实验阶段的重组白细胞介素-10可能被视为一种新的治疗药物。
